| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2478298 | Annales Pharmaceutiques Françaises | 2007 | 5 Pages |
Abstract
As a consequence to the extension of marketing authorization for indications for the use of botulinum toxin type A in 2005, 77% of treated therapeutic indications are now compliant to marketing authorization specifications. Through prescription analysis, in-hospital pharmacists participate in the implementation of guidelines for follow-up and management of medical expenditures.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
M. Villart,